J Antimicrob Chemother 2016; **71**: 3528–3535
doi:10.1093/jac/dkw323 Advance Access publication 15 August 2016

Journal of Antimicrobial Chemotherapy

PCR-based detection of *Aspergillus fumigatus Cyp51A* mutations on bronchoalveolar lavage: a multicentre validation of the AsperGenius assay® in 201 patients with haematological disease suspected for invasive aspergillosis

G. M. Chong[1]*, M. T. van der Beek[2], P. A. von dem Borne[3], J. Boelens[4], E. Steel[5], G. A. Kampinga[6], L. F. R. Span[7], K. Lagrou[8], J. A. Maertens[9], G. J. H. Dingemans[10], G. R. Gaajetaan[10], D. W. E. van Tegelen[10], J. J. Cornelissen[11], A. G. Vonk[12] and B. J. A. Rijnders[1]

[1]Department of Internal Medicine, Section of Infectious Diseases, Erasmus University Medical Center, Rotterdam, The Netherlands; [2]Department of Medical Microbiology, Leiden University Medical Center, Leiden, The Netherlands; [3]Department of Haematology, Leiden University Medical Center, Leiden, The Netherlands; [4]Department of Microbiology, Ghent University Hospital, Ghent, Belgium; [5]Department of Haematology, Ghent University Hospital, Ghent, Belgium; [6]Department of Medical Microbiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; [7]Department of Haematology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; [8]Department of Microbiology and Immunology, KU Leuven—University of Leuven; University Hospitals Leuven, Leuven, Belgium; [9]Department of Microbiology and Immunology, KU Leuven—University of Leuven; Department of Haematology, University Hospitals Leuven, Leuven, Belgium; [10]PathoNostics B.V., Maastricht, The Netherlands; [11]Department of Haematology, Erasmus University Medical Center, Rotterdam, The Netherlands; [12]Department of Medical Microbiology, Erasmus University Medical Center, Rotterdam, The Netherlands

*Corresponding author. Tel: +31644533371; Fax: +31107035945; E-mail: g.chong@erasmusmc.nl

Received 23 March 2016; returned 6 May 2016; revised 6 June 2016; accepted 8 July 2016

Objectives: In patients with invasive aspergillosis (IA), fungal cultures are mostly negative. Consequently, azole resistance often remains undetected. The AsperGenius® multiplex real-time PCR assay identifies clinically relevant *Aspergillus* species and four resistance-associated mutations (RAMs; TR34/L98H/T289A/Y121F) in the *Cyp51A* gene. This multicentre study evaluated the diagnostic performance of this assay on bronchoalveolar lavage (BAL) fluid and correlated the presence of RAMs with azole treatment failure and mortality.

Methods: Stored BAL samples from patients with haematological diseases with suspected IA were used. BAL samples that were galactomannan/culture positive were considered positive controls for the presence of *Aspergillus*. Azole treatment failure and 6 week mortality were compared in patients with and without RAMs that had received ≥5 days of voriconazole monotherapy.

Results: Two hundred and one patients each contributed one BAL sample, of which 88 were positive controls and 113 were negative controls. The optimal cycle threshold cut-off value for the *Aspergillus* species PCR was <38. With this cut-off, the PCR was positive in 74/88 positive controls. The sensitivity, specificity, positive predictive value and negative predictive value were 84%, 80%, 76% and 87%, respectively. 32/74 BAL samples were culture negative. Azole treatment failure was observed in 6/8 patients with a RAM compared with 12/45 patients without RAMs ($P=0.01$). Six week mortality was 2.7 times higher in patients with RAMs (50.0% versus 18.6%; $P=0.07$).

Conclusions: The AsperGenius® assay had a good diagnostic performance on BAL and differentiated WT from *Aspergillus fumigatus* with RAMs, including in culture-negative BAL samples. Most importantly, detection of RAMs was associated with azole treatment failure.

Introduction

Invasive aspergillosis (IA) is the most frequent pulmonary mould infection among immunocompromised patients with haematological diseases and is usually caused by *Aspergillus fumigatus*.[1,2] The triazole voriconazole is currently recommended for first-line therapy.[3] However, (pan)azole resistance in *A. fumigatus* has been reported increasingly over the past decade with a prevalence ranging from 1.0% to as high as 20.0%.[4–11] This is worrisome because a study showed that the mortality in culture-positive IA caused by

© The Author 2016. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com

Downloaded from https://academic.oup.com/jac/article/71/12/3528/2631282 by U.S. Department of Justice user on 17 August 2022

an azole-resistant strain was 88%.[11] Azole resistance is often caused by mutations in the *Cyp51A* gene that encodes the lanosterol 14α-demethylase, the target enzyme for azoles. Two mutation patterns in this gene account for a large part of the azole resistance mechanisms: TR34/L98H and TR46/T289A/Y121F.[6,9–12]

Aspergillus cultures of respiratory specimens are positive in at most 26% of the IA cases.[13,14] Given the low sensitivity of the cultures, most cases are diagnosed indirectly by detection of galactomannan (GM).[13] However, in the absence of a positive culture, azole resistance remains undetected. Thus, the lack of a fast and readily available azole susceptibility test compromises the initiation of adequate treatment in the case of azole resistance. The commercially available AsperGenius® multiplex real-time PCR assay consists of two PCRs: the species PCR identifies the clinically relevant *Aspergillus* species, and the resistance PCR detects the TR34, L98H, T289A and Y121F resistance-associated mutations (RAMs) that represent the prevalent mutation combinations TR34/L98H and TR46/T289A/Y121F in the *Cyp51A* gene. In a recent single-centre study, the diagnostic performance of the species PCR on bronchoalveolar lavage (BAL) samples of patients with haematological diseases showed a sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of 89%, 89%, 73% and 96%, respectively, when a cycle threshold (Ct) value of <36 was used.[15] Moreover, the resistance PCR was able to detect RAMs in a culture-negative patient with IA.[15]

The purpose of this retrospective multicentre study was to confirm the diagnostic performance of the AsperGenius® assay in a large population of patients with haematological diseases and to evaluate if the molecular detection of the above-mentioned RAMs correlates with azole treatment failure and mortality.

Methods

Study design

This retrospective study was performed at three Dutch and two Belgian hospitals (Erasmus University Medical Center, Leiden University Medical Center, University Medical Center Groningen, Ghent University Hospital and University Hospitals Leuven). The AsperGenius® assay was performed on 1 mL stored leftover BAL samples on which GM (Platelia™ Bio-Rad Inc.) and culture had already been performed because of a clinical suspicion of IA. Only BAL samples from patients with haematological diseases were included. The collection of BAL samples ended on 31 May 2015. All available leftover BAL samples with a minimum volume of 1 mL before this date were obtained. BAL samples were stored at −20°C in four hospitals and at −80°C in one hospital. The following information was retrieved from medical files: age, sex, underlying disease, duration of hospitalization, documentation of IA and the antifungal treatment given. In addition, 6 and 12 week mortality was documented. Because this was a retrospective study, no data on the BAL procedure itself was registered.

The study consisted of two parts. First, the optimal Ct value and diagnostic performance of the species probe of the PCR were determined. Second, treatment failure and 6 week mortality were determined in all patients who had received azole monotherapy for at least 5 days and in whom the resistance PCR successfully discriminated WT from *Cyp51A* mutated *A. fumigatus*. Patients with *A. fumigatus* without RAM (=WT) were compared with those with *A. fumigatus* containing a RAM. Patients were excluded from the azole treatment failure analysis if: (i) a non-*A. fumigatus* or mixed infection was present (e.g. *A. fumigatus* and *Aspergillus terreus*); (ii) patients were treated with non-azole therapy or combination therapy; (iii) the antifungal therapy or duration was unknown; or (iv) patients received no therapy. Azole treatment failure was defined as a switch from an azole to any other antifungal drug class. Data of the patient population with haematological diseases of the previous study ($n=10$) were pooled with the data of the current study for the specific analysis of azole treatment failure and 6 week mortality.[15] The pooling of data was deemed necessary and appropriate because of: (i) the rarity of patients infected with RAMs; and (ii) the identical methodology and same study site in both studies.

One BAL sample per patient was included in the study. If for a given patient multiple BAL samples were available, the BAL sample of the period with the highest IA classification was selected. In case of multiple BAL samples for a given patient with the same IA classification, 1 BAL sample was randomly selected.

PathoNostics tested the BAL samples blindly and was not involved in the analysis of the results. G. M. C. and B. J. A. R. analysed the data.

Ethics

The medical ethics committees approved the study under the reference numbers MEC-2014-628, P14.337, UC UZG 2014/1217 and S57319. For one Dutch centre, local approval was not necessary as approval given by another Dutch medical ethics committee also implied approval for that centre. In centres with an opt-out system, all included patients were cross-checked with the list of patients that had objected to the opt-out system. In one centre, opt-out forms were sent to the surviving patients to give them the opportunity to refuse the use of their clinical data.

Categorization of BAL samples

BAL samples with a positive GM (≥1.0) and/or a positive *Aspergillus* culture of the BAL, sputum or lung biopsy (<6 days after the date of the BAL) were considered positive controls for the presence of *Aspergillus* in BAL samples. Negative controls were BAL samples with a negative BAL GM in combination with a negative culture from BAL, sputum or biopsy. BAL samples from patients with only a positive serum GM (≥0.5), but a negative BAL GM, were considered as negative controls as there was no microbiological evidence of the presence of *Aspergillus* in the BAL sample itself on which the PCR was performed.

Definitions of invasive fungal disease

Patients were categorized as having proven, probable or possible invasive fungal disease according to the revised European Organization for Research and Treatment of Cancer/Invasive Infectious Diseases Study Mycoses Group (EORTC/MSG) consensus criteria (available as Supplementary data at *JAC* Online).[16] In addition, patients with appropriate host criteria and positive microbiological findings, but with non-specific radiological features, were classified as having *non-classifiable* disease. Although this category is not included in the EORTC/MSG definitions, in clinical practice these patients are treated similarly to those with probable IA given their similar outcomes.[17]

Processing of BAL samples

One millilitre of the BAL sample was used for DNA extraction. Samples were processed as described previously,[15] with the exception that DNA was extracted from the BAL supernatant and pellet by using a NucliSENS® easyMag® system (bioMérieux). The onboard lysis protocol and 50 μL elution was selected for this purpose before the DNA eluate was used in the AsperGenius® assay. The AsperGenius® assay was performed on the BAL supernatant and pellet separately. A LightCycler 480 II PCR system (Roche) was used to perform the AsperGenius® assay. For the determination of the Ct values, the second derivative function of the LightCycler 480 software (v. 1.5.62) was applied.

Downloaded from https://academic.oup.com/jac/article/71/12/3528/2631282 by U.S. Department of Justice user on 17 August 2022

AsperGenius® multiplex real-time PCR assay

The AsperGenius® multiplex real-time PCR assay (PathoNostics, Maastricht, The Netherlands) was used to detect *Aspergillus* species and *Cyp51A* gene mutations. The species PCR allows for detection of *A. fumigatus* complex, *A. terreus* and *Aspergillus* species by targeting the 28S rRNA multicopy gene. The *A. fumigatus* probe detects the most relevant species of the *Fumigati* complex: *A. fumigatus*, *Aspergillus lentulus* and *Aspergillus felis*. The *Aspergillus* species probe specifically detects *A. fumigatus*, *A. terreus*, *Aspergillus flavus* and *Aspergillus niger*. An internal control is included to monitor for inhibition or manual handling errors. The resistance PCR targets the single-copy *Cyp51A* gene of *A. fumigatus* and detects TR34/L98H/Y121F/T289A mutations to differentiate WT from mutant *A. fumigatus* via melting curve analysis.

Each extracted BAL sample was tested in duplicate and a no template control (blank) was included in each run to exclude contamination. A sample was considered positive when one of the duplicates showed increased fluorescence above the threshold. The positive control from the assay was used as a standard for the melting peaks and was tested simultaneously with the BAL samples to determine whether the melting peak represents WT or *A. fumigatus* with RAM. The resistance PCR was deemed successful when the supernatant or pellet showed melting peaks for (i) at least one of TR34 or L98H, together with (ii) at least one of T289A or Y121F resistance markers.

Statistical analysis

The optimal Ct cut-off and diagnostic performance was determined for the species probe of the PCR using the earlier Ct value of the supernatant or pellet. Using the controls as described above, the receiver operator characteristic (ROC) curve and its area under the curve (AUC) were determined (IBM® SPSS® statistics, v. 21). The closest point of the curve to the (0,1) point and the Youden index were used to further assess the optimal Ct cut-off.[18] The sensitivity, specificity, PPV and NPV were calculated for all BAL samples in total and per hospital. The positive and negative likelihoods were calculated for the optimal Ct value.

As an additional sensitivity analysis, we determined the ROC curves, AUC and diagnostic performance when using patients with EORTC/MSG-proven, probable IA versus patients without IA. This was thought to be appropriate because the EORTC/MSG criteria are often used for antifungal therapy studies. Because clinicians tend to treat patients with non-classifiable IA in the same way as proven or probable IA,[17] we performed a second sensitivity analysis in which patients with proven, probable or non-classifiable IA were compared with patients without IA.

For the azole treatment failure and 6 week mortality analysis, the two-sided Fisher's exact test was used, with a P value <0.05 considered statistically significant.

Results

In total, 228 BAL samples from 201 patients were available. Samples were obtained between December 2007 and May 2015. No patients refused to have their clinical data used for the purpose of this study. As only one BAL per patient was used, 201 BAL samples were available for the analysis. Seven patients with proven, probable or non-classifiable IA were counted as negative controls since there was no evidence of *Aspergillus* in the BAL itself from culture or GM (5 positive serum GM, 1 positive sinus culture and 1 positive lung biopsy culture obtained 16 days after the BAL). The clinical characteristics of the 201 patients are summarized in Table 1.

Eighty-eight BAL samples were positive controls, of which 74 (84.1%) were positive for the species PCR (58 positive in supernatant and pellet, 10 only positive in supernatant and 6 only positive in pellet). The species PCR detected 66 *A. fumigatus*, 2 *A. fumigatus* combined with *A. terreus*, 2 *A. terreus* and 4 *Aspergillus* species. Thirty-two of these 74 (43.2%) BAL samples were culture negative and only GM positive.

Table 1. Clinical characteristics of the 201 haematology patients who contributed BAL fluid samples

Age (years), mean (range)	56.6 (17.5–82.6)
Male, *n* (%)	132 (65.7)
Diagnosis, *n* (%)	
AML	78 (38.8)
ALL	16 (8.0)
CLL	13 (6.5)
myelodysplastic syndrome	17 (8.5)
Hodgkin's lymphoma	10 (5.0)
non-Hodgkin's lymphoma	38 (18.9)
myeloproliferative disorders	8 (4.0)
plasma cell disorders	11 (5.5)
aplastic anaemia	3 (1.5)
other[a]	7 (3.5)
Allogeneic stem cell transplantation, *n* (%)	82 (40.8)
IA, *n* (%)	
proven	9 (4.5)
probable	43 (21.4)
non-classifiable	43 (21.4)
possible	32 (15.9)
no IA	74 (36.8)
BAL GM and/or culture positive or negative, *n* (%)	
GM and culture positive	28 (13.9)
GM positive and culture negative	56 (27.9)
GM negative and culture positive	4 (2.0)
GM and culture negative	113 (56.2)
Treated with following antifungal therapy, *n* (%)[b]	
amphotericin B lipid complex	6 (3.0)
liposomal amphotericin B	40 (19.9)
conventional amphotericin B deoxycholate	4 (2.0)
caspofungin	26 (12.9)
itraconazole	3 (1.5)
posaconazole	18 (9.0)
voriconazole	112 (55.7)
study anidulafungin versus placebo	3 (1.5)
study voriconazole versus isavuconazole	3 (1.5)
study voriconazole versus posaconazole	6 (3.0)
no antifungal therapy	56 (27.9)
Mortality after IA diagnosis, *n* (%)	
at 6 weeks	50 (24.9)
at 12 weeks	65 (32.3)
Hospital admission duration (days), mean (range)	40.7 (2–236)

[a]Monoclonal B cell lymphocytosis, auto-immune haemolytic anaemia, sickle cell disease, haemophagocytic lymphohistiocytosis, T cell prolymphocytic leukaemia.
[b]Some patients were treated with more than one antifungal therapy, and some patients were treated within a clinical trial (indicated by the 'study' prefix) in which the prescribed antifungal therapy was unknown to the physicians.

Downloaded from https://academic.oup.com/jac/article/71/12/3528/2631282 by U.S. Department of Justice user on 17 August 2022



Figure 1. ROC curve of species probe of the AsperGenius® PCR in the BAL fluid samples of the 201 patients with haematological diseases.

Twenty-three BAL samples from negative controls were species PCR positive. Five of these 23 BAL samples were from patients with proven, probable or non-classifiable IA (3 diagnosed on positive serum GM, 1 on positive sinus culture and 1 on positive lung biopsy pathology plus culture). Eleven BAL samples were from patients without IA and 7 from patients with possible IA.

The ROC curve of the species PCR is shown in Figure 1. The diagnostics accuracy as given by AUC was 0.890 (95% CI 0.842–0.939; $P<0.001$). The closest point of the curve to the (0,1) point designated Ct <38 as the optimal cut-off, while the Youden index designated Ct <36 as the optimal cut-off (Table S1). The Ct cut-off of <38 resulted in a sensitivity, specificity, PPV and NPV of 84.09%, 79.65%, 76.29% and 86.54%, respectively. A Ct cut-off of <36 gave values of 70.45%, 95.56%, 92.58% and 80.60%, respectively (Table 2). Because a higher sensitivity was preferred over a higher specificity, the Ct value of <38 was chosen for the purpose of the subsequent analyses that we performed. The positive likelihood ratio was 4.13 and the negative likelihood ratio 0.20. Table 3 shows the distribution of the BAL samples according to their IA classification. Table S2 shows the diagnostic performance per hospital. As a sensitivity analysis, the diagnostic characteristics were calculated when patients with proven or probable IA were considered as positive controls and compared with patients without IA. The sensitivity increased to 88% when the <38 Ct cut-off was used. See Table 2 and Figure S1, for the ROC curves when patients with proven, probable or non-classifiable IA were considered as positive controls.

In the 201 BAL samples, the species PCR was positive in 97 (74 positive controls and 23 negative controls; Figure 2). The resistance PCR was successfully performed in 68/97 BAL samples. Fifty-seven patients had a WT *A. fumigatus* and 11 patients had an *A. fumigatus* with RAM [TR34/L98H mutation ($n=7$), TR46/T289A/Y121F mutation ($n=1$) and TR34/L98H mutation combined with a WT *A. fumigatus* ($n=3$)]. One or two resistance markers were not detected in 9/68 BAL samples (L98H in 4, TR34 in 5 and T289A in 2). However, based on the detection of the other corresponding resistance marker (e.g. successful amplification of L98H in 4 patients in combination with unsuccessful TR34 amplification), a conclusion could be drawn on the presence of *A. fumigatus* WT or resistant due to TR34/L98H or TR46/T289A/Y121F.

For the azole treatment failure and 6 week mortality analysis, resistance data from the 68 patients were included together with 10 patients with haematological diseases from the previous study (8 WT, 1 TR34/L98H and 1 TR46/T289A/Y121F).[15] As such, the total group consisted of 78 patients of whom 65 were infected with WT *A. fumigatus* and 13 with *A. fumigatus* carrying a RAM. Twenty-five of these 78 patients were excluded from the analysis as described in the Methods section and Figure 3. After exclusion, 45 patients with WT *A. fumigatus* remained and 8 with an *A. fumigatus* that contained RAMs. The patients infected with WT had 5 proven, 20 probable, 17 non-classifiable IA and 3 possible IA. In patients infected with *A. fumigatus* containing a RAM, 4 had probable, 3 had non-classifiable and 1 had possible IA. *A. fumigatus* was cultured in 23/53 patients (3 with and 20 without RAMs). Data on antifungal susceptibility testing were available for 7/23 *A. fumigatus* cultures (5 azole susceptible and 2 azole resistant) and correlated with the results of the resistance PCR. Azole treatment failure was observed in 12/45 patients with WT *A. fumigatus* compared with 6/8 patients with *A. fumigatus* with RAM ($P=0.01$). Six week mortality was 2.6 times higher in patients with detected RAM (17.8% without versus 50.0%; $P=0.07$).

Discussion

This retrospective multicentre study showed that the AsperGenius® species PCR has a good diagnostic performance on BAL samples of patients with haematological diseases. The sensitivity, specificity, PPV and NPV were 84%, 80%, 76% and 87%, respectively, when a Ct cut-off of <38 was used.

The two most frequently used statistical methods to analyse a ROC curve are selecting the point closest to (0,1) and the Youden index. In this study, these methods led to contradictory results as

Downloaded from https://academic.oup.com/jac/article/71/12/3528/2631282 by U.S. Department of Justice user on 17 August 2022

Table 2. Diagnostic performance of the species probe of the AsperGenius® PCR according to different Ct cut-offs and positive/negative controls

Ct value cut-off of the AsperGenius® species PCR	Diagnostic performance	Positive control versus negative control BAL samples as defined in this study,[a] $n=201$	Proven, probable or non-classifiable IA versus no IA,[b] $n=169$	Proven or probable IA versus no IA, $n=126$
<36	sensitivity (%)	70.45	68.42	76.92
	specificity (%)	95.58	98.65	98.65
	PPV (%)	92.54	98.48	97.56
	NPV (%)	80.60	70.87	85.88
<37	sensitivity (%)	73.86	71.58	78.85
	specificity (%)	90.27	94.59	94.59
	PPV (%)	85.53	94.44	91.11
	NPV (%)	81.60	72.16	86.42
<38	sensitivity (%)	84.09	83.16	88.46
	specificity (%)	79.65	85.14	85.14
	PPV (%)	76.29	87.78	80.70
	NPV (%)	86.54	79.75	91.30
<39	sensitivity (%)	88.64	87.37	90.38
	specificity (%)	62.83	72.97	72.97
	PPV (%)	65.00	80.58	70.15
	NPV (%)	87.65	81.82	91.53

[a]BAL samples with a positive GM (≥1.0) and/or positive culture for *Aspergillus* of BAL, sputum or lung biopsy at most 5 days from date of the BAL were considered positive controls. BAL samples with a negative BAL GM in combination with a negative culture from BAL, sputum or lung biopsy were considered negative controls.
[b]Proven IA and probable IA were defined according to the revised EORTC/MSG consensus criteria. Non-classifiable was defined as a patient with EORTC/MSG host and microbiological criteria fulfilled and a pulmonary infiltrate without a halo or air-crescent or well-defined nodule. No IA was defined as no proven IA, no probable IA, no non-classifiable IA or no possible invasive fungal disease.

to the most appropriate Ct cut-off values (36 and 38, respectively). Given the important clinical consequences of a missed IA diagnosis, a later Ct cut-off of 38 that results in a better sensitivity may be preferred by the clinician if the resulting loss in specificity is acceptable. Therefore, we favour the use of the Ct cut-off of <38, which is later than the Ct cut-off of <36 that we reported in the previous smaller single-centre study.[15] The current sensitivity was somewhat lower than in the previous single-centre study (89%),[15] and may be explained by the fact that a standard volume of 1 mL of BAL was used in this study versus 1–2 mL in the previous study. The lower volume may have decreased the sensitivity. The difference in sensitivity observed *between* the study centres may be explained by differences in the way the BAL is performed in each centre. For example, centres may differ in the volume used to perform the BAL or a bronchoscopist may lavage two different parts of the lung, but send it in one container to the laboratory, which may result in a diluted DNA content if *Aspergillus* is present in only one part of the lung. Unfortunately, the way the BAL procedure was done in each patient was not recorded. The difference in sensitivity could not be explained by the differences in BAL storage methods. One hospital stored its BAL samples at −80°C and had a sensitivity of 75%, while the other four hospitals stored at −20°C and had a sensitivity of 71%–100%. Furthermore, the difference could not be explained by the duration of BAL storage *before* the PCR was performed because two hospitals contributed BAL samples from the period 2014–2015 and had different sensitivities of 88% and 100%.

As with all diagnostic tests, a test should be interpreted within the context of the prevalence of the disease. When azole resistance is low in a certain area, it is expected that the PPV of the PCR will probably drop. Based on the positive and negative likelihood ratios of 4.13 and 0.20, respectively, one can determine the post-test probability in a Fagan nomogram to take the prevalence in the patient population into account.

On top of the detection of *Aspergillus*, the AsperGenius® resistance PCR was able to differentiate *A. fumigatus* without a RAM (=WT) from RAM-positive *A. fumigatus*, even in culture-negative BAL samples. Most importantly, patients infected with RAM-positive *A. fumigatus* failed significantly more often on azole treatment than those infected with a WT *A. fumigatus* (75% versus 27%; $P=0.01$). Therefore, this study is the first to show that PCR-detected resistance is clinically relevant. The incidence of azole treatment failure and the 6 week mortality was determined in the pooled data of the current and previous study.[15] The sole reason to pool the data of both studies is the fact that azole-resistant IA is still a rare disease with only 13 cases detected in the 78 PCR-positive patients of the 251 patients included in both studies. Given the small numbers, it was not possible to perform a multivariate analysis to investigate other predictors of azole treatment failure.

To date, the AsperGenius® assay has been studied on serum samples of patients with haematological diseases in which the species PCR had a sensitivity and specificity of 79% and 100%, respectively, when a Ct cut-off of 39 was used.[19] In addition to the AsperGenius® assay, other *Aspergillus* PCRs have been tested

Downloaded from https://academic.oup.com/jac/article/71/12/3528/2631282 by U.S. Department of Justice user on 17 August 2022

Table 3. Distribution of the BAL samples according to their IA classification and species probe of the AsperGenius® PCR using a Ct value of <38 as the cut-off

Classification of IA	BAL samples, *n*=201		
	Ct <38	Ct ≥38	total
Proven	9	0	9
GM and culture positive	5	0	
only GM positive	3	0	
only culture positive	1	0	
Probable	37	6	43
GM and culture positive	11	0	
only GM positive	22	6	
only culture positive	4	0	
Non-classifiable	33	10	43
GM and culture positive	12	0	
only GM positive	20	10	
only culture positive	1	0	
Possible	7	25	32
No IA	11	63	74
Total	97	104	201

GM in BAL and serum. Culture in BAL and elsewhere in the body.

on BAL samples and sensitivities varied between 38% and 94%.[20–22] Therefore, the sensitivity of the species PCR found in this study is comparable, but with the added advantage that RAMs are detected simultaneously. There are other PCRs like the AsperGenius® assay that detect *Cyp51A* mutations directly in BAL samples.[23–25] Spiess *et al*.[23,24] described the detection of *Cyp51A* mutations on 189 clinical samples in their first and second studies combined and found the TR34/L98H mutation on two BAL samples and one cerebral biopsy. Zhao *et al*.[25] found the *Cyp51A* mutations M220 and PL216, which are also associated with azole resistance, in 2/94 BAL samples. These studies, along with the current study, show that detection of the *Cyp51A* mutation in BAL samples is possible, as well as in culture-negative BAL samples. The current study is the first to show that the detection of RAMs is clinically associated with azole treatment failure.

The current study has limitations. First, only *Cyp51A* mutations included in the assay can be detected. To date, more than 15 *Cyp51A* gene-mediated resistance mechanisms have been described.[26] The included mutations TR34/L98H and TR46/T298A/Y121F originate from the environment, in contrast to *Cyp51A* mutations that are patient acquired after prolonged azole treatment.[7,27,28] The prevalence for the TR34/L98H mutation can account for up to 90.2% of the azole-resistant *A. fumigatus*, and up to 26.9% for the TR46/T289A/Y121F.[6,9–12] However, the prevalence varies by region. For example, a study from the UK found only two TR34/L98H mutations among the 45 azole-resistant *A. fumigatus* isolates.[7] The assay should therefore be interpreted within the context of the local prevalence of



Figure 2. BAL samples divided according to positive/negative controls and species probe of the AsperGenius® PCR and resistance PCR. Two patients had a coinfection with an *A. fumigatus* and *A. terreus*.

Downloaded from https://academic.oup.com/jac/article/71/12/3528/2631282 by U.S. Department of Justice user on 17 August 2022



Figure 3. Inclusion for azole treatment failure and 6 week mortality analysis.

the *Cyp51A* mutations. In addition to the *Cyp51A* mutations, non-*Cyp51A* mechanisms that confer azole resistance have been reported.[4,6,8–11] Therefore, PCR testing does not replace culture-based susceptibility testing, which should be performed as well. Second, we studied the BAL samples from December 2007 to May 2015. Azole resistance has increased over the past decade.[4–11] Eleven of the 201 (5.5%) patients were infected with an *A. fumigatus* containing a RAM, which may be an underestimate of RAMs in the current population. Lastly, the retrospective nature of the study is another limitation. Antifungal susceptibility testing was not performed routinely in the past. Therefore, the PCR results could only be correlated with the phenotypical resistance in a small portion of the patients. However, in a prospective study, it would be unacceptable to test BAL samples in real time without reporting the detected *Cyp51A* mutations back to the clinician, which obviously would lead to a switch from an azole to a non-azole therapy. Therefore, this retrospective study had the advantage that it became possible to report on eight patients treated with azoles despite the fact that they had been infected with RAM-positive and therefore azole-resistant *A. fumigatus*.

Conclusions

The AsperGenius® assay showed a good diagnostic performance in detecting IA in patients with haematological diseases, and the detection of RAM-positive *A. fumigatus* was associated with azole treatment failure, even when patients were culture negative. Therefore, early detection of RAMs by PCR can lead to prompt adaptation of the antifungal regimen, and hopefully contribute to a more favourable outcome of azole-resistant *A. fumigatus* in future patients.

Acknowledgements

Part of this work was presented at the following conference: 7th Trends in Medical Mycology (TIMM), Lisbon, Portugal, 2015 (Title: 'PCR-based detection of *A. fumigatus* cyp51A mutations on bronchoalveolar lavage can readily predict azole treatment failure. A multicentre validation study in 201 haematology patients with suspected invasive aspergillosis.'; Number: P060).

We would like to thank M. F. Beaumont and M. van der Weg for their assistance on this project.

Funding

This study was carried out as part of our routine work.

Transparency declarations

L. F. R. S. reports speaker fees from Pfizer, Gilead and MSD, conference fees from Pfizer and Gilead, and personal fees from Pfizer.

K. L. reports grants and personal fees from MSD and travel support to conferences and speaker's honorarium from Pfizer and Gilead.

J. A. M. reports grants and personal fees from MSD, Pfizer Inc., Astellas Pharma, Gilead Sciences and Bio-Rad, and personal fees from Basilea and F2G.

G. J. H. D., G. R. G. and D. W. E. v. T. are employees of PathoNostics B.V.

B. J. A. R. reports grants and personal fees from Gilead.

All other authors: none to declare.

Supplementary data

EORTC/MSG consensus criteria, Tables S1 and S2 and Figure S1 are available as Supplementary data at *JAC* Online.

Downloaded from https://academic.oup.com/jac/article/71/12/3528/2631282 by U.S. Department of Justice user on 17 August 2022

References

1 Azie N, Neofytos D, Pfaller M *et al*. The PATH (Prospective Antifungal Therapy) Alliance® registry and invasive fungal infections: update 2012. *Diagn Microbiol Infect Dis* 2012; **73**: 293–300.

2 Montagna MT, Lovero G, Coretti C *et al*. SIMIFF study: Italian fungal registry of mold infections in hematological and non-hematological patients. *Infection* 2014; **42**: 141–51.

3 Walsh TJ, Anaissie EJ, Denning DW *et al*. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. *Clin Infect Dis* 2008; **46**: 327–60.

4 Bader O, Weig M, Reichard U *et al*. *cyp51A*-Based mechanisms of *Aspergillus fumigatus* azole drug resistance present in clinical samples from Germany. *Antimicrob Agents Chemother* 2013; **57**: 3513–7.

5 Fischer J, van Koningsbruggen-Rietschel S, Rietschel E *et al*. Prevalence and molecular characterization of azole resistance in *Aspergillus* spp. isolates from German cystic fibrosis patients. *J Antimicrob Chemother* 2014; **69**: 1533–6.

6 Fuhren J, Voskuil WS, Boel CH *et al*. High prevalence of azole resistance in *Aspergillus fumigatus* isolates from high-risk patients. *J Antimicrob Chemother* 2015; **70**: 2894–8.

7 Howard SJ, Cerar D, Anderson MJ *et al*. Frequency and evolution of azole resistance in *Aspergillus fumigatus* associated with treatment failure. *Emerg Infect Dis* 2009; **15**: 1068–76.

8 Lockhart SR, Frade JP, Etienne KA *et al*. Azole resistance in *Aspergillus fumigatus* isolates from the ARTEMIS global surveillance study is primarily due to the TR/L98H mutation in the *cyp51A* gene. *Antimicrob Agents Chemother* 2011; **55**: 4465–8.

9 Ozmerdiven GE, Ak S, Ener B *et al*. First determination of azole resistance in *Aspergillus fumigatus* strains carrying the TR34/L98H mutations in Turkey. *J Infect Chemother* 2015; **21**: 581–6.

10 van der Linden JW, Arendrup MC, Warris A *et al*. Prospective multicenter international surveillance of azole resistance in *Aspergillus fumigatus*. *Emerg Infect Dis* 2015; **21**: 1041–4.

11 van der Linden JW, Snelders E, Kampinga GA *et al*. Clinical implications of azole resistance in *Aspergillus fumigatus*, The Netherlands, 2007-2009. *Emerg Infect Dis* 2011; **17**: 1846–54.

12 van Ingen J, van der Lee HA, Rijs TA *et al*. Azole, polyene and echinocandin MIC distributions for wild-type, TR34/L98H and TR46/Y121F/T289A *Aspergillus fumigatus* isolates in the Netherlands. *J Antimicrob Chemother* 2015; **70**: 178–81.

13 Marr KA, Schlamm HT, Herbrecht R *et al*. Combination antifungal therapy for invasive aspergillosis: a randomized trial. *Ann Intern Med* 2015; **162**: 81–9.

14 Meersseman W, Lagrou K, Maertens J *et al*. Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients. *Am J Respir Crit Care Med* 2008; **177**: 27–34.

15 Chong GL, van de Sande WW, Dingemans GJ *et al*. Validation of a new *Aspergillus* real-time PCR assay for direct detection of *Aspergillus* and azole resistance of *Aspergillus fumigatus* on bronchoalveolar lavage fluid. *J Clin Microbiol* 2015; **53**: 868–74.

16 De Pauw B, Walsh TJ, Donnelly JP *et al*. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. *Clin Infect Dis* 2008; **46**: 1813–21.

17 Nucci M, Nouer SA, Grazziutti M *et al*. Probable invasive aspergillosis without prespecified radiologic findings: proposal for inclusion of a new category of aspergillosis and implications for studying novel therapies. *Clin Infect Dis* 2010; **51**: 1273–80.

18 Liu X. Classification accuracy and cut point selection. *Stat Med* 2012; **31**: 2676–86.

19 White PL, Posso RB, Barnes RA. Analytical and clinical evaluation of the PathoNostics AsperGenius assay for detection of invasive aspergillosis and resistance to azole antifungal drugs during testing of serum samples. *J Clin Microbiol* 2015; **53**: 2115–21.

20 Torelli R, Sanguinetti M, Moody A *et al*. Diagnosis of invasive aspergillosis by a commercial real-time PCR assay for *Aspergillus* DNA in bronchoalveolar lavage fluid samples from high-risk patients compared to a galactomannan enzyme immunoassay. *J Clin Microbiol* 2011; **49**: 4273–8.

21 Orsi CF, Bettua C, Pini P *et al*. Detection of *Pneumocystis jirovecii* and *Aspergillus* spp. DNA in bronchoalveolar lavage fluids by commercial real-time PCR assays: comparison with conventional diagnostic tests. *New Microbiol* 2015; **38**: 75–84.

22 Frealle E, Decrucq K, Botterel F *et al*. Diagnosis of invasive aspergillosis using bronchoalveolar lavage in haematology patients: influence of bronchoalveolar lavage human DNA content on real-time PCR performance. *Eur J Clin Microbiol Infect Dis* 2009; **28**: 223–32.

23 Spiess B, Postina P, Reinwald M *et al*. Incidence of *cyp51 A* key mutations in *Aspergillus fumigatus*—a study on primary clinical samples of immunocompromised patients in the period of 1995-2013. *PLoS One* 2014; **9**: e103113.

24 Spiess B, Seifarth W, Merker N *et al*. Development of novel PCR assays to detect azole resistance-mediating mutations of the *Aspergillus fumigatus cyp51A* gene in primary clinical samples from neutropenic patients. *Antimicrob Agents Chemother* 2012; **56**: 3905–10.

25 Zhao Y, Stensvold CR, Perlin DS *et al*. Azole resistance in *Aspergillus fumigatus* from bronchoalveolar lavage fluid samples of patients with chronic diseases. *J Antimicrob Chemother* 2013; **68**: 1497–504.

26 Chowdhary A, Sharma C, Hagen F *et al*. Exploring azole antifungal drug resistance in *Aspergillus fumigatus* with special reference to resistance mechanisms. *Future Microbiol* 2014; **9**: 697–711.

27 Snelders E, Huis In 't Veld RA, Rijs AJ *et al*. Possible environmental origin of resistance of *Aspergillus fumigatus* to medical triazoles. *Appl Environ Microbiol* 2009; **75**: 4053–7.

28 van der Linden JW, Camps SM, Kampinga GA *et al*. Aspergillosis due to voriconazole highly resistant *Aspergillus fumigatus* and recovery of genetically related resistant isolates from domiciles. *Clin Infect Dis* 2013; **57**: 513–20.

Downloaded from https://academic.oup.com/jac/article/71/12/3528/2631282 by U.S. Department of Justice user on 17 August 2022